Xlife Sciences : Praesentation

THE LEADING EUROPEAN LIFE SCIENCES INCUBATOR AND ACCELERATOR

Disclaimer

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, INTO THE UNITED STATES OF AMERICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION WOULD BE UNLAWFUL

The presentation has been prepared by Xlife Sciences Ltd. ("Xlife", and together with its subsidiaries, the "Xlife Group") for information and background purposes only. This document is not, and should not be construed as, a prospectus or offering document, and has not been reviewed or approved by any regulatory or supervisory authority. The information does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or a solicitation or invitation of any offer to subscribe for or purchase any loans or securities of or make an investment in Xlife or any other member of the Xlife Group or any other entity in any jurisdiction, and nothing contained therein shall form the basis of, or be relied on in connection with, any contract or commitment whatsoever, in particular, it must not be used in making any investment decision.

No representation, warranty or undertaking, express or implied, is made by Xlife or any member of the Xlife Group or any of their respective affiliates or directors, officers, employees, agents or advisers ("Representatives") or any other person as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained therein or any other statement made or purported to be made in connection with Xlife, the Xlife Group or any member thereof, for any purpose whatsoever, including but not limited to any investment considerations. No responsibility, obligation or liability whatsoever, whether arising in tort, contract or otherwise, is or will be accepted by Xlife or any member of the Xlife Group or any of their respective Representatives or any other person for any loss, cost or damage howsoever arising from any use of the information, or for information or opinions or for any errors, omissions or misstatements contained therein or otherwise arising in connection therewith.

This presentation contains forward-looking statements, including but not limited to, projections of financial developments, market activities, future performance of products and solutions or planned transactions, which involve risks and uncertainties and are based on certain assumptions. These forward-looking statements are subject to change based on known or unknown risks and various other factors, which could cause the actual results, performance or events to differ materially from the statements made herein. If any of these risks and uncertainties materializes or if the assumptions underlying any of Xlife's forward-looking statements prove to be incorrect, the actual results may be materially different from those Xlife expresses or implies by such statements. Xlife does not intend or assume any obligation to update these forward-looking statements since they are based solely on the circumstances at the date of their publication.

The securities mentioned herein will not be registered under the United States Securities Act of 1933, as amended (the "Act"), and such securities may not be offered or sold in the United States of America absent registration or an applicable exemption from registration requirements under the Act. This presentation is not a prospectus for the purposes of Regulation (EU) 2017/1129 (as amended) and Regulation (EU) 2017/1129 as it forms part of domestic law pursuant to the European Union (Withdrawal) Act 2018.

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]

1

COMPANY OVERVIEW

Xlife Sciences is a Swiss life sciences incubator and accelerator.

2019	1	~5.70 M	49.9%
LAUNCH	STOCK EXCHANGE	SHARES	FREE FLOAT
WITH 6 PROJECT COMPANIES	SPARKS SEGMENT SIX SWISS EXCHANGE	5.703.292 SHARES WITH A NOMINAL	43.0% FOUNDERS, 7.1% MANAGEMENT
	SINCE FEBRUARY 2022,	VALUE OF CHF 1
	PREVIOUS MUNICH STOCK EXCHANGE

~200 M	>40/100k
MARKET CAPITALIZATION	INNOVATION PARTNERS
May 2024	WITH UNIVERSITIES, RESARCH INSTITUTIONS &
	INDUSTRY PARTNERS / ACCESS TO SCIENTISTS

24/4/34	>15
PORTFOLIO COMPANIES	EMPLOYEES
IN 4 INVESTMENT PILLARS	XLIFE SCIENCES AG /
WITH 36 PROJECTS	PROJECT COMPANIES

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]

2

BUSINESS MODEL

Xlife Sciences supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts.

~300			~3-5	~1.5 M
INVENTION DISCLOSURES P.A.		NEW PROJECT COMPANIES P.A.	FINANCING
WHERE WE ADD VALUE TO OUR PROJECT COMPANIES	BREAKDOWN BY PROJECT DEVELOPMENT PHASE
PROOF OF		M&A		MARKETING
CONCEPT
HR		STRUCTURING		BUSINESS
		DEVELOPMENT

~500k

POTENTIAL GRANTS

EXIT STRATEGIES

LICENSE DEAL

TRADE SALE

RESEARCH

PATENTING

LICENSING

IPO

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]

3

INVESTMENT PROCESS

		3	4
	2	EXIT
	ACTIVE MANAGEMENT &	STRATEGY
1		SYNERGIES
BUSINESS EVALUATION &
	SCIENTIFIC ASSESSMENT
INITIAL CONTACT &
INVENTION DISCLOSURE

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]

4

COMPANY LEADERSHIP

MANAGEMENT

BOARD OF DIRECTORS

ADVISORY BOARD

Oliver R. Baumann	Carl von Halem
Chief Executive Officer	Chief Financial Officer

David L. Deck	Désirée Dosch
President of the Board	Member of the Board
of Directors	of Directors

Prof. Dr. habil.	Prof. Dr. Ernst
Michael B. Klein	Rietschel
Politics Expert	Immunology Expert

Dr. med. Uwe Rudolf	Dr. med. Ralf
Max Reuter, DM	Oettmeier
Head Physician at	Head Physician at
Klinik Im Leben	Alpstein Clinic

Dr. Frank Plöger	Christian Faber
Chief Scientific Officer	Head of Legal &
	Compliance

Dr. Norbert Windhab	Mark S. Müller
Member of the Board	Member of the Board
of Directors	of Directors

Prof. Dr. Hans-Georg	Prof. Dr. Johannes
Rammensee	Schumacher
Immunology Expert	Human Genetics Expert

Dr. Bernward	Prof. Dr.
Garthoff	Jürgen Eckel
Industry Expert	Diabetes Expert

Beat Kläui

Head of Accounting and Taxes

Oliver R. Baumann

Member of the Board

of Directors

Dr. Christoph

Brücher

Industry Expert

Prof. Dr.

Ulrich Räth

Industry Expert

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]

5

KEY FOCUS AREAS & PROJECT COMPANIES

TECHNOLOGY PLATFORMS

BIOTECH & THERAPIES

®

MEDICAL TECHNOLOGY

ARTIFICIAL INTELIGENCE

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]

6

SELECTED MARKETS

ONCOLOGY

METABOLIC /

INFLAMMATION

MEDICAL DEVICES

3D-PRINTING

DIAGNOSTICS

OBESITY

CRO

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]

7

PORTFOLIO

Our approach is to be in the driver seat. In over 50% of the new project companies, Xlife Sciences initiated the spin-off process directly from and with a university or research institution.

INITIAL PROJECTS #4 (2)

SPIN-OFF #12

STRATEGIC #5 (1)

INDUSTRY JOINT VENTURE #3

25%	14%	51%	100%	75%	License	50%	50%
							®
17%	5%	67%	100%	50%	20%	40%

70%	19%	35%
		JOINT VENTURE PARTNER
100%	70%
		50%	50%
EXITED		EXITED
46%	100%
		60%
100%	100%
Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.ch I [e-mail]			8

PROJECT STAGE

T E C H N O L O G Y P L A T F O R M S

XLIFE

R&D

POC

EXIT

B I O T E C H N O L O G Y & T H E R A P I E S

XLIFE

R&D

POC

EXIT

2023

A R T I F I C I A L I N T E L L I G E N C E

XLIFE

R&D

POC

EXIT

2023

M E D I C A L T E C H N O L O G Y & D I A G N O S T I C S

XLIFE

R&D

POC

EXIT

®

Xlife Sciences AG I Talacker 35 I CH-8001 Zurich I www.xlifesciences.

.ch

9